Ruxolitinib is used in the treatment of chronic idiopathic myelofibrosis and polycythemia vera.
How Ruxolitinib works Ruxolitinib is an anti-cancer medication that functions by inhibiting the action of the abnormal protein responsible for signaling cancer cells to multiply. This mechanism helps to stop or slow the spread of cancer cells.
Common side effects of Ruxolitinib include anemia (low red blood cell count), low blood platelets, dizziness, infection, fatigue, headache, decreased white blood cell count (neutrophils), increased alanine aminotransferase, and bruising.